Calidi Biotherapeutics, Inc. announced that it will receive $3,500,000 in funding on March 8, 2024. The company will issue convertible debt in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.232 USD | -2.93% | +15.42% | -84.64% |
04-16 | Calidi Biotherapeutics Prices $6.1 Million Offering | MT |
03-21 | H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-84.64% | 11.7M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- CLDI Stock
- News Calidi Biotherapeutics, Inc.
- Calidi Biotherapeutics, Inc. announced that it expects to receive $3.5 million in funding